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Viruses of the Adenoviridae family are widespread in society
and are associated with a wide variety of clinical symptoms in
humans, including respiratory, gastrointestinal, and ocular
diseases.
[1] Epidemic keratoconjunctivitis (EKC) is a severe
ocular infection and is caused by the highly contagious
adenoviruses Ad8, Ad19, and Ad37.
[1] Besides keratitis and
conjunctivitis, other common symptoms of EKC are pain,
lacrimation, red and swollen eyes, as well as decreased vision
that may last for months or even years.
[1] No antiviral drugs
are currently available for the treatment of EKC or any other
infection caused by adenoviruses. The initial event leading to
EKC is binding of the viruses to glycans that contain sialic
acid moieties on epithelial cells in the cornea or conjunctiva
through trimeric fiber structures extending from the viral
particles.
[2,3] The receptor-binding domain, the fiber knob, is
located at the C terminus of each fiber and contains three
separate pockets that each can accommodate one sialic acid
residue. Ad37 was recently shown to bind to cell-surface
glycoproteins carrying a glycan structure similar to the GD1a
ganglioside.
[4] The GD1a glycan is a branched hexasaccharide
with a terminal sialic acid residue on each of its two arms.
Structural studies showed that the two sialic acid moieties
dock into two of three sialic acid binding sites in the trimeric
knob of the Ad37 fiber protein. Most likely, multiple fiber
proteins simultaneously engage several host-cell epitopes
containing terminal sialic acids; internalization and subse-
quent infection follow. If these sialic acid–protein interactions
can be blocked, for example, by a multivalent sialic acid
conjugate, infection might be prevented.
To date, several carbohydrate-based or glycomimetic
drugs have reached the market; however, the development
of additional therapies is still hampered by challenges such as
poor absorption and/or rapid elimination.
[5] The topical
administration of sialic acid conjugates directly to the eye,
that is, the site of infection, circumvents many of the
pharmacokinetic hurdles and has the potential to prevent or
even cure EKC. In the search for new antiviral substances
against Ad37, we synthesized and evaluated multivalent
human serum albumin (HSA) conjugates of both 3’-sialyllac-
tose and sialic acid as adenoviral inhibitors.
[6,7] These con-
jugates efficiently inhibited Ad37 cell attachment and the
subsequent infection of human corneal epithelial (HCE) cells.
Both types of conjugates were equally efficient as Ad37
inhibitors.
[6,7] From the crystal structure of the fiber-knob
protein as a complex with sialyllactose, it was evident that the
sialic acid acetamide group is positioned in a relatively large
hydrophobic pocket.
[8] To improve the potency of the more
advantageous multivalent sialic acid conjugates, we used
structure-based design and synthesized a library of ten N-
acyl-modified sialic acid derivatives with the overall goal of
improving hydrophobic interactions and thus affinity and
efficacy.
[9] Unfortunately, none of the designed conjugates
were as potent as the original sialic acid–HSA conjugate,
although X-ray crystallography revealed that the modified
saccharides interacted with the fiber-knob protein as
expected.
[9]
On the basis of the structural features of the interaction of
the GD1a glycan with the Ad37 knob,
[4] and with our previous
results
[6,7,9] in mind, we then designed and synthesized sialic
acid containing compounds by using small non-protein
scaffolds. The crystal structure of the fiber-knob protein
shows that the three known sialic acid binding sites are
separated by distances of about 10  . We therefore consid-
ered the design of a compact and rigid scaffold decorated with
three correctly positioned sialic acids as too complex. Instead
we selected the three small and flexible scaffolds tris(2-
aminoethyl)amine (2), 2-(aminomethyl)-2-methyl-1,3-pro-
panediamine(3), and 2,2-diaminomethyl-1,3-propanediamine
(4) for conjugation with the sialic acid derivative 1
[7] through
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ME0323, and ME0324 in modest to good yields (Scheme 1;
see also the Supporting Information). We reasoned that
longer flexible spacers would enable all three binding pockets
to be occupied simultaneously by one molecule.
The effects of ME0322, ME323, ME0324, sialic acid, and a
17-valent sialic acid–HSA conjugate were first evaluated in
virus-binding experiments (see the Supporting Informa-
tion).
[6,7,9] ME0322, ME0323, and ME0324 all inhibited the
attachment of Ad37 virions to HCE cells in a dose-dependent
manner and were at least two orders of magnitude more
effective than sialic acid. Importantly, the most potent
compound, ME0322, was as efficient as the 17-valent sialic
acid–HSA conjugate (Figure 1a).
[7] To firmly establish the
potential of ME0322 as an anti-adenoviral agent, we eval-
uated the compound further in a cell-based infection assay
(see the Supporting Information).
[6,7,9] Compound ME0322
proved to be very potent and inhibited the infection of HCE
cells by Ad37 virions with an IC50 value of 0.38 mm (Fig-
ure 1b). Remarkably, the trivalent compound ME0322 was
approximately four orders of magnitude more potent than
sialic acid (Figure 1b) and substantially more potent than 3’-
sialyllactose–HSA and sialic acid–HSA conjugates.
[6,9]
To determine the structural features of the Ad37 fiber
knob–ME0322 interaction, we solved the crystal structure of
this complex at a resolution of 2.4   (Figure 2; see also the
Supporting Information, including Table S1). Only the termi-
nal sialic acid residues of ME0322 are visible in the final
electron-density map (see Figure S1 in the Supporting
Information). We did not observe electron density for the
rest of the compound, probably because the flexible linkers
do not make defined contacts with the protein. It is, however,
likely that all three sialic acids in a fiber knob belong to the
same trivalent compound. Analysis of the crystal packing
shows that the distances between sialic acid binding sites in
different knobs are too large to be bridged by a single
ME0322 molecule (data not shown). The binding of all sialic
acid residues and their interactions with their respective
protein chains are identical to the previously established
binding mode between the sialic acid residues of sialyl-a(2,3)-
lactose or the GD1a hexasaccharide and the Ad37 fiber
knob.
[4,8]
Figure 1. Effect of sialic acid containing compounds on adenovirus
type 37 binding to and infection of human corneal cells. a) Extent of
virion binding in the presence of inhibitors at different concentrations.
b) Extent of infection at different concentrations of the inhibitors sialic
acid and ME0322. The control is the value obtained for binding or
infection in the absence of an inhibitor.
Figure 2. Overall structure of the Ad37 fiber head as a complex with
ME0322. The three Ad37 chains A, B, and C are shown as ribbon
tracings and colored green, blue, and gray, respectively. The terminal
sialic acid moietes of ME0322 are bound on top of the fiber head and
are shown in stick representation, with carbon atoms in yellow, oxygen
atoms in red, and nitrogen atoms in blue. The spacers and scaffold
are not shown.
Scheme 1. Synthesis of tri- and tetravalent sialic acid compounds. The
sialic acid squaric decyl ester 1 was coupled to the scaffolds 2, 3, and
4 to form the compounds ME0322, ME0323 and ME0324:a )N,N-
diisopropylethylamine, MeOH, room temperature, 2–8 days, 30–69%.
Communications
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sialic acid conjugate ME0322 for Ad37 fiber knobs immobi-
lized on a CM5 sensor chip by surface plasmon resonance (see
the Supporting Information, including Figure S2). The bind-
ing was shown to fit to a simple one-to-one binding model,
and the calculated Kd value for the interaction of the Ad37
fiber-knob protein with ME0322 was calculated to be 14 mm.
The interaction of the GD1a hexasaccharide with the Ad37
fiber-knob protein, on the other hand, follows a two-to-one
binding model with Kd=19 and 265 mm.
[4] Our results suggest
that the high-affinity interaction results from the occupation
of two of the three sialic acid binding pockets by the two
terminal sialic acids of one GD1a hexasaccharide, and that
another, unknown site is engaged in the low-affinity inter-
action. ME0322 and the GD1a hexasaccharide thus bind to
the fiber-knob protein with similar affinities. Interestingly, the
GD1a hexasaccharide is a poor inhibitor of cell infection
(IC50=0.7 mm),
[4] in contrast to ME0322, which is approx-
imately four orders of magnitude more potent. The number of
components and processes in the cell-based assay, however,
makes it difficult to directly relate calculated affinities
obtained by surface plasmon resonance analysis to potency
in the infection assay.
In conclusion, we have synthesized tri- and tetravalent
sialic acid compounds and evaluated them in an Ad37 cell-
binding assay. The most promising trivalent compound,
ME0322, was subsequently shown to be a very potent
inhibitor of Ad37 infection of human ocular cells. Our
functional and structural data show that ME0322 efficiently
blocks the adenovirus cell-binding protein, the fiber knob.
Therefore, such compounds offer promise as antiviral drugs
for the topical treatment of EKC.
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